Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintained a price target of $72.
August 09, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Cytokinetics and maintained a price target of $72.
The reiteration of a Buy rating and a maintained price target of $72 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100